In order to ensure 2023 billing, testing must be activated before the end of the year, or within 30 days of proband sample collection (if sample was collected in 2023). For Exome, Genome, or Xpanded testing, if you do not expect parental samples to be received in time for testing to be activated with 2023 billing, please contact us at firstname.lastname@example.org to determine how to proceed.
We’ve spent the past two decades building one of the deepest, most sophisticated aggregate rare disease datasets in the genomics industry.
Clinical Exomes & Genomes Sequenced
GeneDx’s rich data and value are grounded in our history and leadership in comprehensive genetic testing, including whole exome sequencing and whole genome sequencing.
What’s different about working with GeneDx? Our genomic tests offer higher yields, provide advanced variant classification, require submission of detailed clinical information, and leverage our expert interpretation skills to generate more robust patient insights and, thus, more valuable scientific evidence for collaborators.
Limited patient pools and geographic dispersion often hinder the clinical trial and natural history study recruitment process. However, BioPharma companies can identify geographical clusters of patients with specific conditions and strategically select trial sites in regions with higher concentrations of eligible patients.
Finding potential patients for clinical trials and natural history studies is one of the most challenging problems facing BioPharma companies. Our unique approach and access to qualified, diverse clinical testing patients can help.
By leveraging comprehensive genomic datasets, researchers can uncover potential therapeutic targets with greater precision and efficiency. Collaborations with GeneDx provide access to extensive repositories built with clinical and genomic data and hold promise to enhance target validation efforts.
Accurate prevalence projections are crucial for optimizing therapeutic development efforts and achieving pre-clinical regulatory approvals. GeneDx can extract reliable prevalence projections for a wide variety of rare diseases based on our 20 years of testing experience.
Many disorders are underrepresented in research and, thus, in peer-reviewed literature. Accurate data points are an imperative element of regulatory submissions, and collaborations with GeneDx can elucidate the answers to supplement gaps in the literature and propel therapeutic development forward.
The GeneDx BioPharma team works with industry partners to understand their unique challenges, discover their goals, and provide tailored solutions.